FOI 9438 – Q2

In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	19	9	10
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	Less than 5	0	Less than 5
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	8	5	Less than 5
Trastuzumab deruxtecan (Enhertu)	7	0	7
Trastuzumab emtansine (Kadcyla)	Less than 5	0	Less than 5
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	23	19	Less than 5
Abemaciclib + Fulvestrant	Less than 5	0	Less than 5
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	19	0	19
Ribociclib + Fulvestrant	Less than 5	0	Less than 5
Capecitabine as a single agent	10	Less than 5	9
Carboplatin + Paclitaxel	0	0	0
Carboplatin + Paclitaxel + Pembrolizumab	Less than 5	Less than 5	0